Alnylam has big ambitions for Amvuttra. But despite an explosive transthyretin amyloid cardiomyopathy (ATTR-CM) launch in 2025, three questions remain: potential upcoming competition from AstraZeneca ...
Is rhythm control underused in ATTR-CM? Drs Kevin Alexander and Ronald Witteles make the case for rethinking how we manage arrhythmias in this disease. Is rhythm control underused in ATTR-CM? Drs ...
Experts weigh prior authorization, step therapy, and 12‑month coverage to balance access and cost for high‑value long‑term therapies. This episode, titled ‘Navigating Benefit Design and Utilization ...
AI technology and cardiac MRI scans were used to create ECV maps of more than 60 patients with ATTR-CM from an international clinical trial. Among the patients in a study, the distribution of ...
Oversubscribed financing led by Frazier Life Sciences with participation from F-Prime, Qiming Venture Partners, SR One and founding investors Cambridge Innovation Capital and Cambridge Enterprise ...
Abstract: In this work we propose to boost video-based person re-identification (Re-ID) by using attribute-enhanced feature presentation. To this end, we not only try to use the ID-relevant attributes ...
Kevin M. Alexander, MD, eagerly awaits the presentation of new amyloid dataat the 2026 ACC meeting in New Orleans and is especially interested in the subgroup analyses from the ATTRibute-CM and HELIOS ...
Black patients with wild-type ATTR-CM had higher N-terminal pro-B-type natriuretic peptide levels than White patients. Racial variations in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels ...
Abstract: As more and more network applications have adopted encryption for user privacy, it poses a great challenge to identify increasing types of encrypted traffic. Recent methods mainly focus on ...
Pooled HELIOS-A/HELIOS-B safety included 707 patients (30.3% hereditary; remainder wild-type) with median 33.4 months of therapy and exposure up to 58 months. Exposure-adjusted overall and serious ...
Correspondence to Professor Steve Vucic, Brain and Nerve Research Center, Concord Clinical School, University of Sydney, Sydney, New South Wales, Australia; steve.vucic{at}sydney.edu.au Hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results